Trastuzumab duocarmazine

Trastuzumab duocarmazine structure.png

Trastuzumab duocarmazine is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive breast cancer. It combines the targeting capabilities of the monoclonal antibody trastuzumab with a cytotoxic agent, duocarmazine, to deliver targeted chemotherapy to cancer cells.

Mechanism of Action

Trastuzumab duocarmazine works by specifically targeting the HER2/neu receptor, which is overexpressed in certain types of breast cancer. The trastuzumab component binds to the HER2 receptor on the surface of cancer cells, facilitating the internalization of the ADC. Once inside the cell, the duocarmazine is released, where it exerts its cytotoxic effects by binding to DNA and disrupting the cell cycle, ultimately leading to cell death.

Clinical Development

Trastuzumab duocarmazine is currently undergoing clinical trials to evaluate its efficacy and safety in patients with HER2-positive breast cancer. Early-phase studies have shown promising results, with significant tumor reduction observed in some patients. Ongoing trials aim to further assess its potential as a treatment option for patients who have developed resistance to other HER2-targeted therapies.

Side Effects

As with other antibody-drug conjugates, trastuzumab duocarmazine can cause a range of side effects. Common adverse effects include fatigue, nausea, and infusion-related reactions. More serious side effects may include myelosuppression, hepatotoxicity, and cardiotoxicity, which require careful monitoring during treatment.

Regulatory Status

As of the latest update, trastuzumab duocarmazine is not yet approved by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug, with ongoing studies to determine its safety and efficacy profile.

Also see

• Antibody-drug conjugate
• Trastuzumab
• HER2/neu
• Breast cancer
• Targeted therapy